INVIVYD INC (IVVD)
Health Care · Monoclonal antibody therapeutics / viral infectious diseases · NASDAQ
Invivyd develops monoclonal antibody therapeutics for serious viral infections, with PEMGARDA approved for COVID-19 emergency use and a pipeline targeting RSV, measles, and other evolving pathogens.
What INVIVYD INC does
Invivyd Inc is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies (mAbs) for the prevention and treatment of serious viral infectious diseases, particularly COVID-19. The company commercializes PEMGARDA® (pemivibart), which received FDA emergency use authorization in March 2024, and is advancing VYD2311, a next-generation mAb candidate for COVID-19, through its REVOLUTION clinical program. The company is building a pipeline targeting additional high-need indications including respiratory syncytial virus (RSV) and measles, with a focus on delivering differentiated, rapidly updatable therapeutics as viral pathogens evolve.
Themes: COVID-19 therapeutics / monoclonal antibodies, Respiratory viral infections (RSV), Monoclonal antibody development, Emergency infectious disease response, Viral evolution countermeasures
Fundamentals
- Price$0.997 as of 2026-08-21 close
- Market cap$294M as of 2026-08-21
- 1-year return+88.8% 2025-08-21 close $0.528 → 2026-08-21 close $0.997
- P/En/a negative earnings
- Net margin-138.9% as of 2026-08-24
- Gross margin+92.9% as of 2026-08-24
- ROE-53.5% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+52.3% as of 2026-08-24
- Beta1.00 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How IVVD compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How INVIVYD INC looks technically
INVIVYD INC (IVVD) is trading 36.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 82 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 69, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, its first since 2026-06-08, pushing above its recent trading range. It is 67.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 36.0% below its 200-day average, the long-term trend line — a long-term downtrend | -36.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $0.7742 | $0.7742 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.56 | $1.56 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Wave structure | its recent swings can be read as a completed five-part downward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes below 0.528. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave downward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 82 trading days ago — a "death cross", a bearish long-term signal | 82 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control | 28.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 69, neither overbought (above 70) nor oversold (below 30) | 69.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($0.552 to $1.05) — its "stochastic" reading is 89 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 89.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.07 | $3.07 |
|---|---|---|
| From the 52-week high | it is 67.5% below its 52-week high (its highest price of the past year) | -67.5% |
| Above the 52-week low | it is 106.4% above its 52-week low (its lowest price of the past year) | +106.4% |
| Below the 52-week high | it is 67.5% below its highest point of the past year | 67.5% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-06-08, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 16 trading days ago | 16 sessions |
| All-time high | its highest closing price on record is $78.82 (set on 2021-11-30) | $78.82 |
| Given back of the 52-week move | over the past year its closes ranged ($0.52 to $2.88), and it has given back well over two thirds of its rise from last year’s low — 80% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.35 to $1.42. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 79.8% |
| From the all-time high | it is 98.7% below its all-time high | -98.7% |
| Nearest price level | it is trading 1.3% below a resistance level at $1.01 — a price it turned at three times since 2026-05-20, most recently on 2026-07-07. Since 2024-08-21 it has 7 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.3% |
| All-time low | its lowest closing price on record is $0.3547 (set on 2025-01-30) | $0.3547 |
| Above the all-time low | it is 181.1% above its all-time low | +181.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0852 between its high and its low — about 8.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0852 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.42 and $0.98 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.42 – $0.7 – $0.98 |
| Typical daily range (% of price) | its price moves about 8.5% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.5% |
| Stretch from the 200-day average | it is trading 6.6 daily ranges below its 200-day average price (36.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.64× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bearish engulfing | 9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 9 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.6% |
|---|---|---|
| Open gap | it gapped 2.6% above the previous close 3 sessions ago and has not traded back through the level it left behind at 0.74 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.6% |
| Gap filled | a 5.7% gap up opened on 2026-08-20 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 43.9 percentage points (the stock gained 46.2% while the market gained 2.3%) | +43.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 13.3 percentage points (the stock lost 10.2% while the market gained 3.1%) | -13.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 46.7 percentage points (the stock lost 35.7% while the market gained 11.1%) | -46.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 68.3 percentage points (the stock gained 88.8% while the market gained 20.5%) | +68.3% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 24.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 23% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $1.29 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -22.6% |
|---|
Price levels it has turned at before
IVVD last closed at $0.997 on 2026-08-21. Since 2024-08-21 it has turned at 7 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.01 | Resistance | 1.3% above the last close | turned there three times · 2026-05-20 to 2026-07-07 |
| $1.06 | Resistance | 6.3% above the last close | turned there three times · 2024-11-07 to 2025-09-29 |
| $0.8941 | Support | 10.3% below the last close | turned there twice · 2024-10-09 to 2025-03-20 |
| $0.8139 | Support | 18.4% below the last close | turned there three times · 2024-09-09 to 2025-08-11 |
| $0.7001 | Support | 29.8% below the last close | turned there twice · 2025-05-23 to 2025-07-07 |
| $2.02 | Resistance | 103.1% above the last close | turned there twice · 2025-10-10 to 2026-03-10 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $0.528.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · lagging the market · Just filled a gap (5%+ closed in the last week) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$10.00 range $10.00 – $10.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IVVD
- Consensus EPS estimate-$0.15 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Company is unprofitable with negative net margin of -138.9% and substantial accumulated deficit of $995.9 million, requiring continued funding to support operations and clinical development programs","Dependence on continued FDA authorization and market adoption of PEMGARDA, which received only emergency use authorization (not full approval) and faces competitive pressures from other COVID-19 therapeutics","Reliance on third parties for clinical trials, manufacturing, and testing; any delays or failures in these partnerships could adversely impact development timelines and commercialization of product candidates"]
What changed in the latest 10-Q
AI-assisted comparison of IVVD's 10-Q filed 2026-05-14 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 2025 Form 10-K filed March 5, 2026 (newer filing) vs. 2024 Form 10-K filed March 20, 2025 (older filing)
- New bullet point about REVOLUTION clinical program for VYD2311 and delivery through 'healthcare system- and patient-friendly means'
- New bullet point about commitment to developing 'robust pipeline' of product candidates
- New bullet point about expanding into RSV and measles as 'high-need indications'
- New bullet point about ability to identify and develop product candidates that 'exert continuous pharmaceutical activity in the face of viral evolution'
- New reference to SPEAR as '(Spike Protein Elimination and Recovery) Study Group' with added parenthetical definition
- Removed:
- Older bullet point stating PEMGARDA was 'designed to keep pace with SARS-CoV-2 viral evolution' (replaced with language about continuous pharmaceutical activity)
- Older bullet point about 'expectations regarding availability of a rapid pathway to potential Biologics License Application (BLA) approval for VYD2311'
- Older bullet point about 'compact pivotal clinical trial' for VYD2311
- Older bullet point referencing specific clinical trials 'DECLARATION and LIBERTY' as part of REVOLUTION program
- Older bullet point about 'aim to develop mAbs' (changed to 'commitment to developing')
- Older bullet point about 'discovery efforts to assess pipeline expansion beyond SARS-CoV-2'
- Older bullet point about 'goal of establishing streamlined development pathways'
- Older bullet point about ability to 'identify and develop future product candidates' (narrowed to remove 'future')
- Reworded:
- Overview sentence changed from 'devoted to delivering' to 'focused on the discovery, development and commercialization of monoclonal antibody therapies for the prevention and treatment' with additional detail
- PEMGARDA description changed from 'designed to keep pace with SARS-CoV-2 viral evolution' to 'designed to exert continuous pharmaceutical activity in the face of viral evolution'
- VYD2311 language changed from 'system- and patient-friendly means' to 'healthcare system- and patient-friendly means' (added 'healthcare')
- Language changed from 'our aim to develop mAbs' to 'our commitment to developing a robust pipeline of product candidates'
- Language changed from 'potentially expanding into other high-need indications' to definitive expansion language with specific mention of RSV and measles
- Removed mention of 'expectations regarding' and 'future product candidates' in favor of present-focused language on continuous pharmaceutical activity capability
- Notes:
- Text is truncated at end of Overview section in both filings; comparison limited to provided excerpts
- Changes reflect updates to forward-looking statements between Q3 2025 filing (Sept 30, 2025 quarter end) and Q1 2026 filing (March 31, 2026 quarter end)
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Most recent open-market transaction: 2026-02-18. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IVVD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding IVVD as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 13,885,348
- Reported value $18,050,954
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
IVVD had 27,804,425 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
IVVD had 9.43% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.89 days to cover at the same settlement.
- Reported short interest (shares) 27,804,425
- Short interest (% of shares outstanding) 9.43%
- Prior settlement (shares) 29,311,996
- Reported change -5.14%
- Days to cover (reported) 8.89
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Eli Lilly (LLY)
- Regeneron Pharmaceuticals (REGN)
- Genmab A/S
- Roche/Genentech
- GSK (GlaxoSmithKline)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IVVD vs…
Frequently asked questions
What does INVIVYD INC (IVVD) do?
Invivyd Inc is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies (mAbs) for the prevention and treatment of serious viral infectious diseases, particularly COVID-19. The company commercializes PEMGARDA® (pemivibart), which received FDA emergency use authorization in March 2024, and is advancing VYD2311, a next-generation mAb candidate for COVID-19, through its REVOLUTION clinical program.
What sector is INVIVYD INC (IVVD) in?
INVIVYD INC (IVVD) is classified in the Health Care sector. Its industry is Monoclonal antibody therapeutics / viral infectious diseases. It trades on NASDAQ.
Who are INVIVYD INC's (IVVD) competitors?
Notable peers of INVIVYD INC (IVVD) include Eli Lilly, Regeneron Pharmaceuticals, Genmab A/S, Roche/Genentech and GSK (GlaxoSmithKline). This peer set is informational only — not financial advice.
Is INVIVYD INC (IVVD) overbought or oversold right now?
INVIVYD INC (IVVD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 69, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IVVD come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.